Aviron, SmithKline deal

Aviron and SmithKline announced an agreement to develop and commercialize vaccines against Epstein-Barr virus (EBV). Aviron will provide the technology to produce the antigens and the material for clinical trials. SmithKline will be responsible for clinical development, manufacturing and commercialization, and will have exclusive rights to produce and market any therapeutic and prophylactic vaccines resulting from the collaboration. The vaccine is in preclinical development. ...